HPV-associated cancers: insights into the mechanistic scenario and latest updates
Tóm tắt
Từ khóa
Tài liệu tham khảo
Nwokolo N, Barton S. Sexually transmitted diseases of the vulva (Ridley’s The Vulva). 2009, pp. 44–70.
de Sanjosé S, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis,“ (in eng). Lancet Infect Dis. Jul 2007;7(7):453–9.
Bansal A, Singh MP, Rai B. “Human papillomavirus-associated cancers: a growing global problem,“ (in eng), Int J Appl Basic Med Res, vol. 6, no. 2, pp. 84 – 9, Apr-Jun 2016.
“IARC monographs on the evaluation of carcinogenic risks to humans. Volume 97. 1,3-butadiene, ethylene oxide and vinyl halides (vinyl fluoride, vinyl chloride and vinyl bromide),“ (in eng), IARC Monogr Eval Carcinog Risks Hum, vol. 97, pp. 3-471, 2008.
Markowitz LE et al. “Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP),“ (in eng), MMWR Recomm Rep, vol. 63, no. Rr-05, pp. 1–30, Aug 29 2014.
Senkomago V, Henley SJ, Thomas CC, Mix JM, Markowitz LE, Saraiya M. “Human papillomavirus-attributable cancers - United States, 2012–2016,“ (in eng), MMWR Morb Mortal Wkly Rep, vol. 68, no. 33, pp. 724–8, Aug 23 2019.
de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. “Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis,“ (in eng), Lancet Glob Health, vol. 8, no. 2, pp. e180-e190, Feb 2020.
Arbyn M, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis,“ (in eng). Lancet Glob Health. Feb 2020;8(2):e191–e203.
Cramer JD, Hicks KE, Rademaker AW, Patel UA, Samant S. Validation of the eighth edition american Joint Committee on Cancer staging system for human papillomavirus-associated oropharyngeal cancer,“ (in eng). Head Neck. Mar 2018;40(3):457–66.
Høxbroe Michaelsen S, Grønhøj C, Høxbroe Michaelsen J, Friborg J, von Buchwald C. Quality of life in survivors of oropharyngeal cancer: a systematic review and meta-analysis of 1366 patients,“ (in eng). Eur J Cancer. Jun 2017;78:91–102.
Caparrotti F et al. “Osteoradionecrosis of the mandible in patients with oropharyngeal carcinoma treated with intensity-modulated radiotherapy,“ (in eng), Cancer, vol. 123, no. 19, pp. 3691–3700, Oct 1 2017.
de Almeida JR et al. “A systematic review of transoral robotic surgery and radiotherapy for early oropharynx cancer: a systematic review,“ (in eng), Laryngoscope, vol. 124, no. 9, pp. 2096 – 102, Sep 2014.
Machtay M et al. “Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis,“ (in eng), J Clin Oncol, vol. 26, no. 21, pp. 3582–9, Jul 20 2008.
Chera BS et al. “Phase II trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal squamous cell carcinoma,“ (in eng), J Clin Oncol, vol. 37, no. 29, pp. 2661–9, Oct 10 2019.
Ferris RL et al. “Phase II randomized trial of Transoral surgery and low-dose intensity modulated Radiation Therapy in Resectable p16 + locally Advanced Oropharynx Cancer: an ECOG-ACRIN Cancer Research Group Trial (E3311),“ (in eng), J Clin Oncol, vol. 40, no. 2, pp. 138–49, Jan 10 2022.
Ma DJ et al. “Phase II evaluation of aggressive dose de-escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx squamous cell carcinoma,“ (in eng), J Clin Oncol, vol. 37, no. 22, pp. 1909–18, Aug 1 2019.
Gillison ML et al. “Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial,“ (in eng), Lancet, vol. 393, no. 10166, pp. 40–50, Jan 5 2019.
Pignata S, et al. The MITO CERV-2 trial: a randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer,“ (in eng). Gynecol Oncol. Jun 2019;153(3):535–40.
Lee NY et al. “Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial,“ (in eng), Lancet Oncol, vol. 22, no. 4, pp. 450–462, Apr 2021.
Yan F, Cowell LG, Tomkies A, Day AT. Therapeutic vaccination for HPV-Mediated cancers,“ (in eng). Curr Otorhinolaryngol Rep. 2023;11(1):44–61.
Bosch FX, De Sanjosé S. “Chapter 1: Human papillomavirus and cervical cancer—burden and assessment of causality,“ JNCI monographs, vol. 2003, no. 31, pp. 3–13, 2003.
Morshed K, Polz-Gruszka D, Szymański M, Polz-Dacewicz M. “Human Papillomavirus (HPV) - structure, epidemiology and pathogenesis,“ (in eng), Otolaryngol Pol, vol. 68, no. 5, pp. 213-9, Sep-Oct 2014.
zur Hausen H. “Papillomaviruses and cancer: from basic studies to clinical application,“ (in eng), Nat Rev Cancer, vol. 2, no. 5, pp. 342 – 50, May 2002.
Jackson S, Harwood C, Thomas M, Banks L, Storey A. Role of bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins,“ (in eng). Genes Dev. Dec 1 2000;14(23):3065–73.
Yim EK, Park JS. “The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis,“ (in eng), Cancer Res Treat, vol. 37, no. 6, pp. 319 – 24, Dec 2005.
Szymonowicz KA, Chen J. “Biological and clinical aspects of HPV-related cancers,“ (in eng), Cancer Biol Med, vol. 17, no. 4, pp. 864–78, Nov 15 2020.
Jeon S, Allen-Hoffmann BL, Lambert PF. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells,“ (in eng). J Virol. May 1995;69(5):2989–97.
Peitsaro P, Johansson B, Syrjänen S. “Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique,“ (in eng), J Clin Microbiol, vol. 40, no. 3, pp. 886 – 91, Mar 2002.
Scheffner M, Münger K, Byrne JC, Howley PM. “The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines,“ (in eng), Proc Natl Acad Sci U S A, vol. 88, no. 13, pp. 5523-7, Jul 1 1991.
Scheffner M, Huibregtse JM, Howley PM. “Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53,“ (in eng), Proc Natl Acad Sci U S A, vol. 91, no. 19, pp. 8797 – 801, Sep 13 1994.
Li S, et al. Ubiquitination of the HPV Oncoprotein E6 is critical for E6/E6AP-Mediated p53 degradation,“ (in eng). Front Microbiol. 2019;10:2483.
Barr AR, et al. DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression,“ (in eng). Nat Commun. Mar 20 2017;8:14728.
Abbas T, Dutta A. “p21 in cancer: intricate networks and multiple activities,“ (in eng), Nat Rev Cancer, vol. 9, no. 6, pp. 400 – 14, Jun 2009.
Pal A, Kundu R. Human papillomavirus E6 and E7: the cervical Cancer hallmarks and targets for Therapy,“ (in eng). Front Microbiol. 2019;10:3116.
Li J, Poi MJ, Tsai MD. “Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer,“ (in eng), Biochemistry, vol. 50, no. 25, pp. 5566–82, Jun 28 2011.
Doorbar J. “Molecular biology of human papillomavirus infection and cervical cancer,“ (in eng), Clin Sci (Lond), vol. 110, no. 5, pp. 525 – 41, May 2006.
Cubie HA. “Diseases associated with human papillomavirus infection,“ (in eng), Virology, vol. 445, no. 1–2, pp. 21–34, Oct 2013.
Lucido CT et al. “Innervation of cervical carcinoma is mediated by cancer-derived exosomes,“ (in eng), Gynecol Oncol, vol. 154, no. 1, pp. 228–235, Jul 2019.
Spurgeon ME, Lambert PF. “Human Papillomavirus and the Stroma: Bidirectional Crosstalk during the Virus Life Cycle and Carcinogenesis,“ (in eng), Viruses, vol. 9, no. 8, Aug 9 2017.
Surviladze Z, Sterkand RT, Ozbun MA. Interaction of human papillomavirus type 16 particles with heparan sulfate and syndecan-1 molecules in the keratinocyte extracellular matrix plays an active role in infection,“ (in eng). J Gen Virol. Aug 2015;96(8):2232–41.
Delvenne P et al. “The organotypic culture of HPV-transformed keratinocytes: an effective in vitro model for the development of new immunotherapeutic approaches for mucosal (pre)neoplastic lesions,“ (in eng), Vaccine, vol. 19, no. 17–19, pp. 2557-64, Mar 21 2001.
McLaughlin-Drubin ME, Meyers C. Propagation of infectious, high-risk HPV in organotypic “raft” culture,“ (in eng). Methods Mol Med. 2005;119:171–86.
Hamada K, Shirakawa T, Gotoh A, Roth JA, Follen M. “Adenovirus-mediated transfer of human papillomavirus 16 E6/E7 antisense RNA and induction of apoptosis in cervical cancer,“ (in eng), Gynecol Oncol, vol. 103, no. 3, pp. 820 – 30, Dec 2006.
Zhen S, Lu J, Liu YH, Chen W, Li X. Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout,“ (in eng). Cancer Gene Ther. Apr 2020;27:3–4.
Jiang E, Yan T, Xu Z, Shang Z. “Tumor Microenvironment and Cell Fusion,“ (in eng), Biomed Res Int, vol. 2019, p. 5013592, 2019.
Poltavets V, Kochetkova M, Pitson SM, Samuel MS. The role of the Extracellular Matrix and its Molecular and Cellular regulators in Cancer Cell plasticity,“ (in eng). Front Oncol. 2018;8:431.
McBride AA, Münger K. “Expert Views on HPV Infection,“ (in eng), Viruses, vol. 10, no. 2, Feb 24 2018.
Boon SS, Banks L. High-risk human papillomavirus E6 oncoproteins interact with 14-3-3ζ in a PDZ binding motif-dependent manner,“ (in eng). J Virol. Feb 2013;87(3):1586–95.
Chen J. Signaling pathways in HPV-associated cancers and therapeutic implications,“ (in eng). Rev Med Virol. Mar 2015;25(1):24–53.
Takebe N et al. “Targeting notch, hedgehog, and wnt pathways in cancer stem cells: clinical update,“ (in eng), Nat Rev Clin Oncol, vol. 12, no. 8, pp. 445 – 64, Aug 2015.
Rath G, Jawanjal P, Salhan S, Nalliah M, Dhawan I. “Clinical significance of inactivated glycogen synthase kinase 3β in HPV-associated cervical cancer: relationship with Wnt/β-catenin pathway activation,“ (in eng), Am J Reprod Immunol, vol. 73, no. 5, pp. 460 – 78, May 2015.
Yang HJ. “Aberrant DNA methylation in cervical carcinogenesis,“ (in eng), Chin J Cancer, vol. 32, no. 1, pp. 42 – 8, Jan 2013.
Zheng ZM, Wang X. “Regulation of cellular miRNA expression by human papillomaviruses,“ (in eng), Biochim Biophys Acta, vol. 1809, no. 11–2, pp. 668 – 77, Nov-Dec 2011.
Jiang N, Xie F, Chen L, Chen F, Sui L. The effect of TLR4 on the growth and local inflammatory microenvironment of HPV-related cervical cancer in vivo,“ (in eng). Infect Agent Cancer. 2020;15:12.
Bozdayi G et al. “Is Human Papillomavirus and Helicobacter pylori Related in Gastric Lesions?,“ (in eng), Clin Lab, vol. 65, no. 10, Oct 1 2019.
Snietura M et al. “Potential role of human papilloma virus in the pathogenesis of gastric cancer,“ (in eng), World J Gastroenterol, vol. 20, no. 21, pp. 6632-7, Jun 7 2014.
Wang H et al. “Associations Between Gastric Cancer Risk and Virus Infection Other Than Epstein-Barr Virus: A Systematic Review and Meta-analysis Based on Epidemiological Studies,“ (in eng), Clin Transl Gastroenterol, vol. 11, no. 7, p. e00201, Jul 2020.
Rajendra K, Sharma P. “Viral Pathogens in Oesophageal and Gastric Cancer,“ (in eng), Pathogens, vol. 11, no. 4, Apr 15 2022.
Steenbergen RD, de Wilde J, Wilting SM, Brink AA, Snijders PJ, Meijer CJ. “HPV-mediated transformation of the anogenital tract,“ (in eng), J Clin Virol, vol. 32 Suppl 1, pp. S25-33, Mar 2005.
Herrero R et al. “Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study,“ (in eng), J Natl Cancer Inst, vol. 95, no. 23, pp. 1772-83, Dec 3 2003.
Śnietura M, Jaworska M, Pigłowski W, Goraj-Zając A, Woźniak G, Lange D. High-risk HPV DNA status and p16 (INK4a) expression as prognostic markers in patients with squamous cell cancer of oral cavity and oropharynx,“ (in eng). Pol J Pathol. 2010;61(3):133–9.
Khurshid A, Kazuya N, Hanae I, Manabu I. “Infection of human papillomavirus (HPV) and Epstein-Barr virus (EBV) and p53 expression in human esophageal carcinoma,“ (in eng), J Pak Med Assoc, vol. 48, no. 5, pp. 138 – 42, May 1998.
Koshiol J, et al. The gastric cardia is not a target for human papillomavirus-induced carcinogenesis,“ (in eng). Cancer Epidemiol Biomarkers Prev. Apr 2010;19(4):1137–9.
Yuan XY, Wang MY, Wang XY, Chang AY, Li J. Non-detection of Epstein-Barr virus and human papillomavirus in a region of high gastric cancer risk indicates a lack of a role for these viruses in gastric carcinomas,“ (in eng). Genet Mol Biol. Jul 2013;36(2):183–4.
Lawson JS, et al. Human papilloma virus identification in breast Cancer patients with previous cervical neoplasia,“ (in eng). Front Oncol. 2015;5:298.
Widschwendter A, Brunhuber T, Wiedemair A, Mueller-Holzner E, Marth C. “Detection of human papillomavirus DNA in breast cancer of patients with cervical cancer history,“ (in eng), J Clin Virol, vol. 31, no. 4, pp. 292–7, Dec 2004.
Hennig EM, Suo Z, Thoresen S, Holm R, Kvinnsland S, Nesland JM. “Human papillomavirus 16 in breast cancer of women treated for high grade cervical intraepithelial neoplasia (CIN III),“ (in eng), Breast Cancer Res Treat, vol. 53, no. 2, pp. 121 – 35, Jan 1999.
Bodaghi S, Wood LV, Roby G, Ryder C, Steinberg SM, Zheng ZM. “Could human papillomaviruses be spread through blood?,“ (in eng), J Clin Microbiol, vol. 43, no. 11, pp. 5428–34, Nov 2005.
Chang P et al. “Absence of human papillomavirus in patients with breast cancer in north-west China,“ (in eng), Med Oncol, vol. 29, no. 2, pp. 521-5, Jun 2012.
Islam MS, Chakraborty B, Panda CK. Human papilloma virus (HPV) profiles in breast cancer: future management,“ (in eng). Ann Transl Med. May 2020;8(10):650.
Park IH, et al. High volumetric breast density predicts risk for breast cancer in postmenopausal, but not premenopausal, korean women,“ (in eng). Ann Surg Oncol. Dec 2014;21(13):4124–32.
Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. “Human papillomavirus and cervical cancer,“ (in eng), Lancet, vol. 382, no. 9895, pp. 889 – 99, Sep 7 2013.
Di Lonardo A, Venuti A, Marcante ML. Human papillomavirus in breast cancer,“ (in eng). Breast Cancer Res Treat. 1992;21(2):95–100.
Khodabandehlou N et al. “Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins,“ (in eng), BMC Cancer, vol. 19, no. 1, p. 61, Jan 14 2019.
Sigaroodi A, Nadji SA, Naghshvar F, Nategh R, Emami H, Velayati AA. “Human papillomavirus is associated with breast cancer in the north part of Iran,“ (in eng), ScientificWorldJournal, vol. 2012, p. 837191, 2012.
Fackenthal JD, Olopade OI. “Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations,“ (in eng), Nat Rev Cancer, vol. 7, no. 12, pp. 937 – 48, Dec 2007.
Rosen EM, Fan S, Isaacs C. “BRCA1 in hormonal carcinogenesis: basic and clinical research,“ (in eng), Endocr Relat Cancer, vol. 12, no. 3, pp. 533 – 48, Sep 2005.
Santivasi WL et al. “Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer,“ (in eng), Br J Cancer, vol. 113, no. 3, pp. 453–9, Jul 28 2015.
Esquivel-Velázquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, Morales-Montor J. The role of cytokines in breast cancer development and progression,“ (in eng). J Interferon Cytokine Res. Jan 2015;35(1):1–16.
Welte T, Zhang XH. “Interleukin-17 Could Promote Breast Cancer Progression at Several Stages of the Disease,“ (in eng), Mediators Inflamm, vol. 2015, p. 804347, 2015.
Gupta S, Gupta S. “Role of human papillomavirus in oral squamous cell carcinoma and oral potentially malignant disorders: A review of the literature,“ (in eng), Indian J Dent, vol. 6, no. 2, pp. 91 – 8, Apr-Jun 2015.
Wang J, Aldabagh B, Yu J, Arron ST. Role of human papillomavirus in cutaneous squamous cell carcinoma: a meta-analysis,“ (in eng). J Am Acad Dermatol. Apr 2014;70(4):621–9.
Tommasino M. “HPV and skin carcinogenesis,“ (in eng), Papillomavirus Res, vol. 7, pp. 129–131, Jun 2019.
Howley PM, Pfister HJ. “Beta genus papillomaviruses and skin cancer,“ (in eng), Virology, vol. 479–80, pp. 290–6, May 2015.
Gheit T. Mucosal and cutaneous human papillomavirus infections and Cancer Biology,“ (in eng). Front Oncol. 2019;9:355.
Accardi R, Gheit T. “Cutaneous HPV and skin cancer,“ (in eng), Presse Med, vol. 43, no. 12 Pt 2, pp. e435-43, Dec 2014.
Arron ST, Ruby JG, Dybbro E, Ganem D, Derisi JL. Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma,“ (in eng). J Invest Dermatol. Aug 2011;131(8):1745–53.
Tampa M et al. “The Role of Beta HPV Types and HPV-Associated Inflammatory Processes in Cutaneous Squamous Cell Carcinoma,“ (in eng), J Immunol Res, vol. 2020, p. 5701639, 2020.
Bouwes Bavinck JN, et al. Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma,“ (in eng). Cancer Res. Dec 1 2010;70(23):9777–86.
Andersson K et al. “Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions,“ (in eng), Cancer Epidemiol Biomarkers Prev, vol. 17, no. 1, pp. 189 – 95, Jan 2008.
Zamani M, et al. The current epidemic of HPV-associated oropharyngeal cancer: an 18-year danish population-based study with 2,169 patients,“ (in eng). Eur J Cancer. Jul 2020;134:52–9.
Wittekindt C, et al. Increasing incidence rates of Oropharyngeal squamous cell carcinoma in Germany and significance of Disease Burden attributed to human papillomavirus,“ (in eng). Cancer Prev Res (Phila). Jun 2019;12(6):375–82.
Strober W, et al. Two for the price of one: prevalence, demographics and treatment implications of multiple HPV mediated Head and Neck Cancers,“ (in eng). Oral Oncol. Jan 2020;100:104475.
Joseph AW et al. “Molecular etiology of second primary tumors in contralateral tonsils of human papillomavirus-associated index tonsillar carcinomas,“ (in eng), Oral Oncol, vol. 49, no. 3, pp. 244-8, Mar 2013.
Dong H, et al. Current status of human papillomavirus-related Head and Neck Cancer: from viral genome to Patient Care,“ (in eng). Virol Sin. Dec 2021;36(6):1284–302.
Zapatka M, et al. The landscape of viral associations in human cancers,“ (in eng). Nat Genet. Mar 2020;52(3):320–30.
Albers A et al. “Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck,“ (in eng), Cancer Res, vol. 65, no. 23, pp. 11146–55, Dec 1 2005.
Luo X et al. “HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING,“ (in eng), J Clin Invest, vol. 130, no. 4, pp. 1635–52, Apr 1 2020.
Lyford-Pike S et al. “Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma,“ (in eng), Cancer Res, vol. 73, no. 6, pp. 1733–41, Mar 15 2013.
Cillo AR et al. “Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer,“ (in eng), Immunity, vol. 52, no. 1, pp. 183–199.e9, Jan 14 2020.
Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer,“ (in eng). Nat Rev Cancer. Jan 2011;11(1):9–22.
Taberna M, Mena M, Pavón MA, Alemany L, Gillison ML, Mesía R. “Human papillomavirus-related oropharyngeal cancer,“ (in eng), Ann Oncol, vol. 28, no. 10, pp. 2386–98, Oct 1 2017.
Bravo IG, Félez-Sánchez M. “Papillomaviruses: viral evolution, cancer and evolutionary medicine,“ (in eng), Evol Med Public Health, vol. 2015, no. 1, pp. 32–51, Jan 28 2015.
Bosch FX et al. “Comprehensive control of human papillomavirus infections and related diseases,“ (in eng), Vaccine, vol. 31 Suppl 6, pp. G1-31, Dec 30 2013.
Muñoz N et al. “Epidemiologic classification of human papillomavirus types associated with cervical cancer,“ (in eng), N Engl J Med, vol. 348, no. 6, pp. 518 – 27, Feb 6 2003.
Ghittoni R, Accardi R, Chiocca S, Tommasino M. “Role of human papillomaviruses in carcinogenesis,“ (in eng), Ecancermedicalscience, vol. 9, p. 526, 2015.
Roberts S, Evans D, Mehanna H, Parish JL. Modelling human papillomavirus biology in oropharyngeal keratinocytes,“ (in eng). Philos Trans R Soc Lond B Biol Sci. May 27 2019;374(1773):20180289.
Pan C, Issaeva N, Yarbrough WG. HPV-driven oropharyngeal cancer: current knowledge of molecular biology and mechanisms of carcinogenesis,“ (in eng). Cancers Head Neck. 2018;3:12.
Bae J-M. “Human papillomavirus 16 infection as a potential risk factor for prostate cancer: an adaptive meta-analysis,“ Epidemiol health, vol. 37, 2015.
Yang L, et al. Worldwide prevalence of human papillomavirus and relative risk of prostate cancer: a meta-analysis. Sci Rep. 2015;5(1):1–10.
Terris MK, Peehl DM. “Human papillomavirus detection by polymerase chain reaction in benign and malignant prostate tissue is dependent on the primer set utilized,“ Urology, vol. 50, no. 1, pp. 150–156, 1997.
Patel P, Nayak JG, Biljetina Z, Donnelly B, Trpkov K. Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy. Can J Urol. 2015;22(6):8056–62.
Brossner C, Madersbacher S, de Mare P, Ponholzer A, Al-Ali B, Rauchenwald M. Follow-up of men obtaining a six-core versus a ten-core benign prostate biopsy 7 years previously. World J Urol. 2005;23(6):419–21.
Dillner J, et al. Sero-epidemiologal association between human‐papillomavirus infection and risk of prostate cancer. Int J Cancer. 1998;75(4):564–7.
Adami H-O, Kuper H, Andersson S-O, Bergström R, Dillner J. Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2003;12(9):872–5.
Tang K-W, Alaei-Mahabadi B, Samuelsson T, Lindh M, Larsson E. The landscape of viral expression and host gene fusion and adaptation in human cancer. Nat Commun. 2013;4(1):1–9.
Chen AC-H, et al. Human papillomavirus in benign prostatic hyperplasia and prostatic adenocarcinoma patients. Pathol Oncol Res. 2011;17(3):613–7.
Glenn WK, et al. High risk human papilloma viruses (HPVs) are present in benign prostate tissues before development of HPV associated prostate cancer. Infect agents cancer. 2017;12(1):1–10.
de Freitas AC, Gurgel AP, de Lima EG. De França São Marcos, and C. M. M. do Amaral, “Human papillomavirus and lung cancinogenesis: an overview. J Cancer Res Clin Oncol. 2016;142(12):2415–27.
Wu D-W, Liu W-S, Wang J, Chen C-Y, Cheng Y-W, Lee H. Reduced p21WAF1/CIP1 via alteration of p53-DDX3 pathway is Associated with Poor Relapse-Free Survival in Early-Stage Human Papillomavirus–Associated Lung Cancerp21 Reduction promotes HPV-Associated Tumorigenesis. Clin Cancer Res. 2011;17(7):1895–905.
Lai M-C, Chang W-C, Shieh S-Y, Tarn W-Y. DDX3 regulates cell growth through translational control of cyclin E1. Mol Cell Biol. 2010;30(22):5444–53.
Kaufman RH, Bornstein J, Gordon AN, Adam E, Kaplan AL, Adler-Storthz K. Detection of human papillomavirus DNA in advanced epithelial ovarian carcinoma. Gynecol Oncol. 1987;27(3):340–9.
Lai C-H, et al. Human papillomavirus in benign and malignant ovarian and endometrial tissues. Int J Gynecol Pathology: Official J Int Soc Gynecol Pathologists vol. 1992;11(3):210–5.
Wu Q, Guo M, Lu Z, Li T, Qiao H, Ke Y. Detection of human papillomavirus-16 in ovarian malignancy. Br J Cancer. 2003;89(4):672–5.
Anttila M, Syrjänen S, Ji H, Saarikoski S, Syrjänen K. Failure to demonstrate human papillomavirus DNA in epithelial ovarian cancer by general primer PCR. Gynecol Oncol. 1999;72(3):337–41.
Kuscu E, Ozdemir B, Erkanli S, Haberal A. HPV and p53 expression in epithelial ovarian carcinoma. Eur J Gynaecol Oncol. 2005;26(6):642–5.
Crook T, et al. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. The Lancet. 1992;339(8801):1070–3.
Kmet LM, Cook LS, Magliocco AM. “A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors,“ Cancer, vol. 97, no. 2, pp. 389–404, 2003.
Ku JL, Kim WH, Park HS, Kang SB, Park JG. Establishment and characterization of 12 uterine cervical-carcinoma cell lines: common sequence variation in the E7 gene of HPV‐16‐positive cell lines. Int J Cancer. 1997;72(2):313–20.
Thomas M, Pim D, Banks L. “The role of the E6-p53 interaction in the molecular pathogenesis of HPV,“ Oncogene, vol. 18, no. 53, pp. 7690–7700, 1999.
Bodaghi S, Yamanegi K, Xiao S-Y, Da Costa M, Palefsky JM, Zheng Z-M. Colorectal papillomavirus infection in patients with colorectal cancer. Clin Cancer Res. 2005;11(8):2862–7.
Bootsma D, Kraemer K, Cleaver J, Hoeijmakers J. “The genetic basis of human cancer,“ New York: McGraw Hill, pp. 245 – 74, 1998.
Kirgan D, Manalo P, Hall M, McGregor B. Association of human papillomavirus and colon neoplasms. Arch Surg. 1990;125(7):862–5.
Cheng J, Sheu L, Meng C, Lee W, Lin J. “Detection of human papillomavirus DNA in colorectal carcinomas by polymerase chain reaction,“ Gut, vol. 37, no. 1, pp. 87–90, 1995.
Stratton KL, Culkin DJ. “A contemporary review of HPV and penile cancer,“ Oncology, vol. 30, no. 3, pp. 245–249, 2016.
Bravo IG, Félez-Sánchez M. “Papillomaviruses Viral evolution, cancer and evolutionary medicine,“ Evolution, medicine, and public health, vol. 2015, no. 1, pp. 32–51, 2015.
Williams VM, Filippova M, Filippov V, Payne KJ, Duerksen-Hughes P. Human papillomavirus type 16 E6* induces oxidative stress and DNA damage,“ (in eng). J Virol. Jun 2014;88(12):6751–61.
Choi YM, Lee SY, Kim BJ. “Naturally Occurring Hepatitis B Virus Mutations Leading to Endoplasmic Reticulum Stress and Their Contribution to the Progression of Hepatocellular Carcinoma,“ (in eng), Int J Mol Sci, vol. 20, no. 3, Jan 30 2019.
Ivanov AV et al. “Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis,“ (in eng), Oncotarget, vol. 8, no. 3, pp. 3895–3932, Jan 17 2017.
Hu J et al. “Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy,“ (in eng), Theranostics, vol. 10, no. 26, pp. 11921–11937, 2020.
Best SR, Niparko KJ, Pai SI. “Biology of human papillomavirus infection and immune therapy for HPV-related head and neck cancers,“ (in eng), Otolaryngol Clin North Am, vol. 45, no. 4, pp. 807 – 22, Aug 2012.
Wei L, Gravitt PE, Song H, Maldonado AM, Ozbun MA. “Nitric oxide induces early viral transcription coincident with increased DNA damage and mutation rates in human papillomavirus-infected cells,“ (in eng), Cancer Res, vol. 69, no. 11, pp. 4878-84, Jun 1 2009.
Li XQ et al. “The diagnosis of cystinosis in patients reveals new CTNS gene mutations in the chinese population,“ (in eng), J Pediatr Endocrinol Metab, vol. 32, no. 4, pp. 375–82, Apr 24 2019.
Zhou C, Tuong ZK, Frazer IH. Papillomavirus Immune Evasion Strategies Target the infected cell and the local Immune System,“ (in eng). Front Oncol. 2019;9:682.
Tobouti PL, Bolt R, Radhakrishnan R, de Sousa S, Hunter KD. “Altered Toll-like receptor expression and function in HPV-associated oropharyngeal carcinoma,“ (in eng), Oncotarget, vol. 9, no. 1, pp. 236–248, Jan 2 2018.
Gutiérrez-Hoya A, Soto-Cruz I. “NK Cell Regulation in Cervical Cancer and Strategies for Immunotherapy,“ (in eng), Cells, vol. 10, no. 11, Nov 10 2021.
Deligeoroglou E et al. “HPV infection: immunological aspects and their utility in future therapy,“ (in eng), Infect Dis Obstet Gynecol, vol. 2013, p. 540850, 2013.
Medda A, Duca D, Chiocca S. “Human Papillomavirus and Cellular Pathways: Hits and Targets,“ (in eng), Pathogens, vol. 10, no. 3, Feb 25 2021.
Xie Y et al. “PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (review),“ Mol Med Rep, 2018.
Csolle MP, Ooms LM, Papa A, Mitchell CA. “PTEN and Other PtdIns(3,4,5)P(3) Lipid Phosphatases in Breast Cancer,“ (in eng), Int J Mol Sci, vol. 21, no. 23, Dec 2 2020.
Rehbein U et al. “The TSC Complex-mTORC1 Axis: from lysosomes to stress granules and back,“ (in English), Front Cell Dev Biology Mini Rev vol. 9, 2021-October-29 2021.
Du L et al. “Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGFβ signaling,“ Oncogene, vol. 35, no. 35, pp. 4641–4652, 2016/09/01 2016.
Bossler F, Hoppe-Seyler K, Hoppe-Seyler F. PI3K/AKT/mTOR signaling regulates the Virus/Host cell crosstalk in HPV-Positive cervical Cancer cells. Int J Mol Sci. 2019;20(9):2188.
Zhang L, Wu J, Ling MT, Zhao L, Zhao KN. The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses,“ (in eng). Mol Cancer. Apr 17 2015;14:87.
Lee HC, Lim S, Han JY. “Wnt/β-catenin signaling pathway activation is required for proliferation of chicken primordial germ cells in vitro,“ (in eng), Sci Rep, vol. 6, p. 34510, Sep 30 2016.
Li Z, Xu Z, Duan C, Liu W, Sun J, Han B. Role of TCF/LEF transcription factors in Bone Development and Osteogenesis. Int J Med Sci. 2018;15(12):1415–22.
Koni M, Pinnarò V, Brizzi MF. “The Wnt Signalling Pathway: A Tailored Target in Cancer,“ (in eng), Int J Mol Sci, vol. 21, no. 20, Oct 18 2020.
Sharma A, Mir R, Galande S. “Epigenetic regulation of the Wnt/β-Catenin signaling pathway in Cancer,“ (in English), Front Genet Rev vol. 12, 2021-September-06 2021.
Cheng YM, Chou CY, Hsu YC, Chen MJ, Wing LY. The role of human papillomavirus type 16 E6/E7 oncoproteins in cervical epithelial-mesenchymal transition and carcinogenesis,“ (in eng). Oncol Lett. Mar 2012;3(3):667–71.
Eblen ST. Extracellular-regulated kinases: signaling from ras to ERK Substrates to control Biological Outcomes,“ (in eng). Adv Cancer Res. 2018;138:99–142.
Xie J, et al. 5-aminolevulinic acid photodynamic therapy reduces HPV viral load via autophagy and apoptosis by modulating Ras/Raf/MEK/ERK and PI3K/AKT pathways in HeLa cells,“ (in eng). J Photochem Photobiol B. May 2019;194:46–55.
Morales-Garcia V, et al. The high-risk HPV E6 proteins modify the activity of the eIF4E protein via the MEK/ERK and AKT/PKB pathways,“ (in eng). FEBS Open Bio. Dec 2020;10(12):2541–52.
Liu F et al. “ERK Signaling pathway is involved in HPV-16 E6 but not E7 Oncoprotein-Induced HIF-1α protein Accumulation in NSCLC cells,“ (in eng), Oncol Res, vol. 23, no. 3, pp. 109 – 18, 2016.
Rasi Bonab F, et al. Molecular pathways in the development of HPV-induced cervical cancer,“ (in eng). Excli j. 2021;20:320–37.
O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention,“ (in eng). Annu Rev Med. 2015;66:311–28.
Katturajan R et al. “Immunomodulatory Role of Thioredoxin Interacting Protein in Cancer’s Impediments: Current Understanding and Therapeutic Implications,“ (in eng), Vaccines (Basel), vol. 10, no. 11, Nov 10 2022.
Krump NA, You J. Molecular mechanisms of viral oncogenesis in humans,“ (in eng). Nat Rev Microbiol. Nov 2018;16(11):684–98.
Morgan EL, Macdonald A. Autocrine STAT3 activation in HPV positive cervical cancer through a virus-driven Rac1—NFκB—IL-6 signalling axis. PLoS Pathog. 2019;15(6):e1007835.